Report Type: Therapy Reports
Report Category: Oncology
Report Subcategory: Humoral Hypercalcemia of Malignancy
Price: $ 2999.00
Date: December 2021

Humoral Hypercalcemia of Malignancy: Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Humoral Hypercalcemia of Malignancy 
Humoral Hypercalcemia of Malignancy is a condition in which the parathyroid hormone-related protein (PTHrP) was isolated from specific tumors as the primary cause of HHM and is overexpressed by many types of neoplasms, also induced by intrahepatic cholangiocarcinoma (ICC) or gastric cancer (GC).

Top 10 Companies:
The Procter & Gamble Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Bayer AG
Novartis AG
Merck & Co Inc
Sanofi
Abbott Laboratories
Amgen Inc
Asahi Kasei Corp